Jyong Biotech Ltd. Ordinary Shares (MENS) Stock Price & Analysis
Jyong Biotech Ltd. Ordinary Shares (MENS) — MoonshotScore 31/100 (Weak band), calculated Nov 18, 2026. Price $1.75 (-5.91%), as of the Nov 19, 2026 trading session; market cap $133M.
Educational signal · not a buy or sell recommendation · How to read this
Jyong Biotech Ltd. Ordinary Shares · MENS · NASDAQ
Jyong Biotech Ltd. is a Taiwan-based biopharmaceutical company specializing in the development of plant-derived drugs for urinary system diseases. Their pipeline includes drug candidates in Phase III, Phase II, and pre-clinical stages, targeting conditions like benign prostatic hyperplasia and prostate cancer.
Price as of Nov 19, 2026
Key Statistics
MoonshotScore v2 · Jyong Biotech Ltd. Ordinary Shares (MENS)
WeakWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
A fragile balance sheet and stalling growth. The score also carries a risk penalty for a bankruptcy-risk score in the distress zone. Business Quality: Solid; Financial Safety: Fragile; Valuation: Fair; Growth Durability: Shrinking; Momentum: Slipping.
- Altman Z -2.32 · Piotroski F 3
- ROE 19.4% · ROA -22.5% · current ratio 0.45 · earnings yield -3.6%
Holding back: balance-sheet strain, soft growth, weak price trend
Helping: an attractive price
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 31 | Weak | |
| 32 | Weak | |
| 32 | Weak | |
| 32 | Weak | |
| 31 | Weak | |
| 31 | Weak |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $1.75 | |
| Change on the day | -5.91% | |
| 52-week range | $1.43 – $40.25 | |
| Market capitalisation | $133M | — |
| Shares traded on the day | 80.0K |
Price & events
Other perspectives
Council score for Jyong Biotech Ltd. Ordinary Shares (MENS): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
5-Factor Breakdown
Legends Council
6 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Oct 18, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 10, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Sep 10, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is Jyong Biotech Ltd. Ordinary Shares (MENS), and what does it report?
Short answer
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Jyong Biotech Ltd. Ordinary Shares (MENS) is listed on NASDAQ. It employs 27 people and is led by Fu-Feng Kuo. The market values it at $133M.
What are the financial strengths and risks for Jyong Biotech Ltd. Ordinary Shares (MENS)?
Short answer · as of
The MoonshotScore pillars rate an attractive price as strengths. What is holding it back is balance-sheet strain, soft growth, weak price trend. The distress and quality screens read Altman Z -2.32 · Piotroski F 3. Trailing ratios: ROE 19.4% · ROA -22.5% · current ratio 0.45 · earnings yield -3.6%.
Data-derived red flags
- Financial-distress signal — its Altman Z-Score of -2.32 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
How does Jyong Biotech Ltd. Ordinary Shares compare with its peers?
Short answer
Jyong Biotech Ltd. Ordinary Shares's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
| Company | Price | Market value | Score |
|---|---|---|---|
| $13.33 Nov 18, 2026 | $471M | 91 5-pillar Nov 18, 2026 | |
| $9.07 Nov 19, 2026 | $540M | 91 5-pillar Nov 18, 2026 | |
| $3.06 Nov 19, 2026 | $258M | 90 5-pillar Nov 18, 2026 | |
| $11.25 Nov 18, 2026 | $102M | 82 5-pillar Nov 18, 2026 | |
| $15.26 Nov 18, 2026 | $85.5M | 82 5-pillar Nov 18, 2026 | |
| $3.89 Nov 18, 2026 | $169M | 72 5-pillar Nov 18, 2026 | |
| $1.88 Nov 19, 2026 | $178M | 69 5-pillar Nov 18, 2026 | |
| $9.28 Nov 19, 2026 | $545M | 68 5-pillar Nov 18, 2026 | |
| $3.13 Nov 19, 2026 | $481M | 60 5-pillar Nov 18, 2026 | |
| $6.78 Nov 19, 2026 | $541M | 60 5-pillar Nov 18, 2026 | |
| $56.31 Nov 19, 2026 | $2.76B | 45 5-pillar Nov 18, 2026 | |
| $16.10 Nov 19, 2026 | $3.12B | 38 5-pillar Nov 18, 2026 | |
| Jyong Biotech Ltd. Ordinary Shares (MENS) — this page | $1.75 | $133M | 31 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held MENS in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported MENS in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What Investors Ask About Jyong Biotech Ltd. Ordinary Shares (MENS)
These answers are editorial: they are written from question templates that restate figures shown above. They are not part of the source register.
What does the MoonshotScore mean for MENS?
MENS carries the MoonshotScore stated above — the Weak band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers. Jyong Biotech Ltd. is a Taiwan-based biopharmaceutical company specializing in the development of plant-derived drugs for urinary system diseases.
Is MENS a good stock to buy?
Stock Expert AI does not rate MENS buy, sell or hold. Jyong Biotech Ltd. Ordinary Shares carries a MoonshotScore, in the Weak band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the MENS stock price today?
The last price recorded for Jyong Biotech Ltd. Ordinary Shares (MENS), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What are the key factors to evaluate for MENS?
Jyong Biotech Ltd. Ordinary Shares (MENS) holds a MoonshotScore in the low range. PCP is in Phase II clinical trials for prostate cancer, offering further potential upside in the oncology space. Not financial advice.
How frequently does MENS data refresh on this page?
MENS's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven MENS's recent stock price performance?
Jyong Biotech Ltd. Ordinary Shares (MENS) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Focus on plant-derived drugs provides a unique selling proposition. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider MENS overvalued or undervalued right now?
Jyong Biotech Ltd. Ordinary Shares (MENS) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Can I buy fractional shares of MENS?
Fractional-share availability for Jyong Biotech Ltd. Ordinary Shares (MENS) depends on your brokerage, account and supported securities. Check the broker's current eligibility, minimums and fees before placing an order.
How can I track MENS's earnings and financial reports?
Jyong Biotech Ltd. Ordinary Shares (MENS) reports quarterly earnings approximately 4-6 weeks after each fiscal quarter ends. You can track earnings dates, revenue and EPS estimates, and actual results on this page's Financials tab. Earnings surprises (beats or misses) often cause significant short-term price moves. Your brokerage can send alerts for MENS earnings announcements.
Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated May 10, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 11 figures on this page — 4 from Financial Modeling Prep (FMP), 6 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com